Este podcast médico presenta una discusión entre los Drs. Sarimar Agosto, Alejandro Román-González y Camilo Jiménez sobre el manejo del feocromocitoma y paraganglioma. Manejo multidisciplinario esencial (endocrinología, oncología, cirugía, genética, radiología nuclear). Referir pacientes a centros de excelencia. Cada caso requiere individualización del tratamiento según progresión, localización tumoral y estado global del paciente.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This NETCast episode features Dr. Uday Grewal hosting a discussion with Drs. Aman Chauhan, Renuka Iyer, and Shagufta Shaheen on the complexities of hybrid neuroendocrine cancers. The panel explores transformation cases, mixed histology, and emerging DLL3-targeted therapies with lung cancer and CAR-T expertise.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This NETCast episode from the 2025 NANETS Symposium features Dr. Theodora Dimitra hosting a discussion with Drs. Alexandria Phan, Paul Herr, Dawn Quelle, and Andrew Bellizzi on a range of hot topics. The panel discusses challenging NET clinical scenarios including biomarkers, GLP-1 medications, and surgical decision-making.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode of NETCast features Dr. Thorvardur Halfdanarson (Mayo Clinic oncologist) and Burt Rosen (patient advocate) discussing artificial intelligence's role in transforming healthcare, particularly for NET patients. Both guests agree AI represents a truly transformative shift—not just another overhyped technology—with potential to revolutionize drug discovery, clinical trial design, and most importantly, move medicine from population-based treatment to individualized care. They also discuss key ethical considerations such as data ownership, patient consent for AI use in care, and ensuring models are trained on diverse populations to avoid amplifying existing biases.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode of NETcast features a "presidential panel" of three distinguished NANETS leaders: Dr. Jennifer Chan (president 2025, Dana-Farber), Dr. Simran Singh (incoming president, Sunnybrook), and Dr. Thorvardur Halfdanarson (president emeritus, Mayo Clinic). The discussion covers transformative developments in NET management over the past decade, including radiopharmaceuticals, targeted therapies, and the recognition that NETs may be less rare than previously thought. The experts explore the future of alpha and beta particle therapy retreatment protocols, challenges in biomarker development, and the importance of treatment sequencing given disease heterogeneity. The panel also discusses the importance of mentorship and the welcoming nature of the NET community in nurturing early-career researchers, while acknowledging that future progress will likely come through incremental advances and optimal treatment sequencing rather than single breakthrough therapies.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode of NETCast features a panel on NET patient advocacy. They explore why advocacy is critical for this rare cancer, discussing challenges patients face at diagnosis, the importance of education and resources, research funding obstacles, and political advocacy efforts. The panel emphasizes that patients should be active participants in advocacy—whether through contacting reprsentatives, supporting research organizations, or engaging in educational initiatives—to make this "invisible" disease visible and drive meaningful change in treatment and outcomes.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This podcast episode discusses the current state of neuroendocrine tumors in Latin America, focusing on the challenges and advancements in diagnosis and treatment. Experts from various countries share insights on the importance of education, registration, and multidisciplinary approaches in managing these tumors. The role of international societies like NANETS in supporting research and education is emphasized, along with the need for increased participation in clinical trials and improved access to treatment options for patients.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this conversation, Jason Starr and Jessica Thomas discuss the critical intersection of mental health and oncology. They explore personal experiences with mental health challenges, the prevalence of burnout among healthcare providers, and the importance of resilience and wellness strategies. The discussion also delves into compassion fatigue, the necessity of setting boundaries for self-care, and the value of community support in navigating these challenges. The conversation emphasizes that mental health is a journey and encourages open dialogue about struggles in the healthcare field.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.